Benevolentai Ltd. has submitted a clinical trial application (CTA) to the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) for BEN-8744, an oral, peripherally restricted, small-molecule phosphodiesterase 10 (PDE10) inhibitor in development as a first-in-class treatment for ulcerative colitis.